Trial Profile
Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CARFI
- 11 Jan 2022 This trial has been completed in Norway, according to European Clinical Trials Database.
- 01 Jan 2022 Status changed from active, no longer recruiting to completed, according to results published in the European Journal of Haematology .
- 30 Aug 2020 This trial has been completed in Lithuania, according to European Clinical Trials Database.